TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Quantum Biopharma ( (TSE:QNTM) ) just unveiled an update.
On October 2, 2025, Quantum BioPharma announced it received final reports for two key studies on its potential breakthrough drug, Lucid-MS, for multiple sclerosis. These reports are crucial for supporting an Investigational New Drug application with the US FDA, moving the company closer to initiating a Phase 2 clinical trial. This development marks a significant milestone in Quantum BioPharma’s efforts to position Lucid-MS as a first-in-class treatment for MS, potentially enhancing its market presence and offering new hope for stakeholders involved in MS treatment.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for treating neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company, through its subsidiary Lucid Psycheceuticals Inc., is advancing its lead compound, Lucid-MS, which targets myelin degradation in multiple sclerosis. Quantum BioPharma also holds strategic investments and retains a stake in Unbuzzd Wellness Inc., which markets the OTC product unbuzzd.
Average Trading Volume: 3,695
Technical Sentiment Signal: Buy
Current Market Cap: C$89.48M
See more data about QNTM stock on TipRanks’ Stock Analysis page.